Guardant Health Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Guardant Health şirketinin kazançları yıllık ortalama -48.5% oranında azalırken, Healthcare sektörünün kazançları yıllık 7.2% oranında artan oldu. Gelirler yıllık ortalama 36.9% oranında artan oldu.

Anahtar bilgiler

-48.5%

Kazanç büyüme oranı

4.8%

EPS büyüme oranı

Healthcare Sektör Büyümesi	15.7%
Gelir büyüme oranı	36.9%
Özkaynak getirisi	-352.0%
Net Marj	-140.6%
Son Kazanç Güncellemesi	30 Sep 2022

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Guardant Health nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

XTRA:5GH Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 22	431	-606	444	340
30 Jun 22	408	-551	420	311
31 Mar 22	391	-419	400	287
31 Dec 21	374	-406	399	263
30 Sep 21	344	-409	399	230
30 Jun 21	324	-379	390	196
31 Mar 21	298	-336	357	168
31 Dec 20	287	-254	299	150
30 Sep 20	271	-185	239	135
30 Jun 20	258	-120	183	124
31 Mar 20	245	-77	154	107
31 Dec 19	214	-76	140	86
30 Sep 19	184	-76	128	77
30 Jun 19	145	-87	115	67
31 Mar 19	111	-97	102	59
31 Dec 18	91	-85	90	51
30 Sep 18	78	-75	74	42
30 Jun 18	67	-84	76	35
31 Mar 18	57	-83	69	29
31 Dec 17	50	-89	66	26
31 Dec 16	25	-46	36	11

Kaliteli Kazançlar: 5GH şu anda kârlı değil.

Büyüyen Kar Marjı: 5GH şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 5GH kârlı değildir ve zararlar son 5 yılda yılda 48.5% oranında artmıştır.

Büyüme Hızlandırma: 5GH 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 5GH kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare sektörüyle ( 40.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 5GH hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -352.01% ) sahiptir.

Guardant Health Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Recent updates

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Guardant Health, Inc. to Appeal Federal District Court Verdict

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Health, Inc. Announces Management Changes

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer

Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy

Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients

Senior Vice President of People recently sold €212k worth of stock

Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations

Second quarter 2022 earnings released: US$2.25 loss per share (vs US$0.96 loss in 2Q 2021)

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Guardant Health, Inc. Appoints Steve E. Krognes as Class III Director, Effective June 30, 2022

Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-Of-Its Kind Prospective Study At Digestive Disease Week 2022

First quarter 2022 earnings released: US$1.21 loss per share (vs US$1.09 loss in 1Q 2021)

Guardant Health, Inc. Provides Revenue Guidance for the Year 2022

Guardant Health, Inc. Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults

Guardant Health, Inc. to Report Q1, 2022 Results on May 05, 2022

Guardant Health, Inc. Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting

Guardant Health, Inc. Announces That Stanley Meresman Will Not Stand for Re-Election to the Company’s Board of Directors

Guardant Health, Inc. Provides Revenue Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Guardant Health, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium

Guardant Health, Inc. Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults

Guardant Health Reaches Target Enrollment of 12,750 Patients in Eclipse Pivotal Study for Its Lunar-2 Blood Test to Detect Colorectal Cancer

Co-Founder recently bought €8.9m worth of stock